While the current influx of biotech IPOs is a positive sign for the industry, historical data shows that excessive IPO activity often coincides with tops in major biotech indices like the XBI. This is a counterintuitive risk for investors to monitor.

When the IPO window opens, nearly every stakeholder—from bankers and lawyers to VCs and management—is financially motivated to go public. This collective "irrational exuberance" can lead to a rush of mixed-quality companies, perpetuating the industry's historical boom-bust IPO cycles.

The recent biotech funding "winter" thawed as large pharmaceutical companies began addressing their massive patent cliffs. This existential threat spurred a wave of M&A transactions, which in turn injected capital and confidence back into the market, enabling smaller biotechs to raise funds through follow-on offerings and IPOs.

Unlike the 2020-2022 bubble, the expected wave of biotech IPOs features mid-to-late-stage companies with de-risked assets. The market's recent discipline, forced by a tough funding environment, has created a backlog of high-quality private companies that are better prepared for public markets than their predecessors.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

The robust performance of early 2026 follow-on offerings, which were upsized and traded significantly above issue price, serves as a strong, real-time indicator of high investor enthusiasm and available capital. This suggests a bullish sentiment and a receptive market for further biotech financing.

The current IPO window sees companies with significant clinical data going public. The previously closed market forced them to advance programs with private funding, resulting in higher-quality offerings compared to the pre-clinical companies that IPO'd during the last boom.

The biotech industry is entering a paradoxical period. Financial markets show signs of recovery with rising follow-ons and potential IPOs, suggesting a bear market end. However, this optimism is contrasted by significant uncertainty and political turmoil at key US agencies like the FDA and NIH, creating a challenging operating environment for innovation.

The closed IPO window forced many private biotech companies to achieve significant clinical milestones, like Phase 2 proof-of-concept, while still private. This has created an unusual cohort of well-seasoned, de-risked companies with attractive valuations, poised to be highly appealing to public investors.